期刊
FUTURE MICROBIOLOGY
卷 6, 期 4, 页码 433-439出版社
FUTURE MEDICINE LTD
DOI: 10.2217/FMB.11.25
关键词
disseminated Mycobacterium avium; ethambutol; moxifloxacin; optimized dosing; pharmacokinetics-pharmacodynamics
类别
Disseminated Mycobacterium avium complex (MAC) is treated with a macrolide and ethambutol. However, the kill rates are extremely slow so that therapy takes many months to years to achieve and even then more than 40% of patients are not completely cured. Recent studies have demonstrated that assays that detect extracellular MAC have a limited predictive value. Antibiotics kill at a much slower and more disappointing rate against bacilli within macrophages. Use of pharmacodynamic/pharmacokinetic models has resulted in design of new doses and dosing schedules for disseminated MAC, as well as new susceptibility breakpoints for ethambutol and moxifloxacin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据